Patents by Inventor Anna Jen
Anna Jen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20140343324Abstract: Biomaterials containing a three-dimensional polymeric network formed from the reaction of a composition containing at least a first synthetic precursor molecule having n nucleophilic groups and a second precursor molecule having m electrophilic groups wherein the sum of n+m is at least five and wherein the sum of the weights of the first and second precursor molecules is in a range from about 8 to about 16% b weight of the composition, preferably from about 10 to about 15%, more preferably from about 12 to about 14.5% by weight of the composition. In one embodiment, the first and second precursor molecules are polyethylene glycols functionalized with nucleophilic and electrophilic groups, respectively. In a preferred embodiment, the nucleophilic groups are amino and/or thiol groups and the electrophilic groups are conjugated, unsaturated groups.Type: ApplicationFiled: May 21, 2014Publication date: November 20, 2014Applicants: Eidgenossische Technische Hochschule Zürich, Universität ZürichInventors: Matthias Lütolf, Jason C. Schense, Anna Jen, Marina Capone, Jeffrey A. Hubbell
-
Patent number: 8226942Abstract: Compositions for wound healing, use of the compositions, and kits and methods of using thereof are described herein. In a preferred aspect, the compositions are suitable for use in a method for forming a fibrin matrix or foam that can be applied or injected at the site of need. In another preferred aspect, the compositions are also suitable for use in methods for forming enhanced controlled delivery fibrin matrices that can be administered as gels or foams.Type: GrantFiled: December 23, 2008Date of Patent: July 24, 2012Assignee: Kuros Biosurgery AGInventors: Gaëlle Charier, Manuela Müller-Maissen, Anna Jen
-
Patent number: 8034618Abstract: Proteins are incorporated into protein or polysaccharide matrices for use in tissue repair, regeneration and/or remodeling and/or drug delivery. The proteins can be incorporated so that they are released by degradation of the matrix, by enzymatic action and/or diffusion. As demonstrated by the examples, one method is to bind heparin to the matrix by either covalent or non-covalent methods, to form a heparin-matrix. The heparin then non-covalently binds heparin-binding growth factors to the protein matrix. Alternatively, a fusion protein can be constructed which contains a crosslinking region such as a factor XIIIa substrate and the native protein sequence. Incorporation of degradable linkages between the matrix and the bioactive factors can be particularly useful when long-term drug delivery is desired, for example in the case of nerve regeneration, where it is desirable to vary the rate of drug release spatially as a function of regeneration, e.g.Type: GrantFiled: February 27, 2007Date of Patent: October 11, 2011Assignees: Eldgenossische Technische Hochschule Zurich, Universitat ZurichInventors: Matthias Lutolf, Jason C. Schense, Jeffrey A. Hubbell, Anna Jen
-
Publication number: 20090169539Abstract: Compositions for wound healing, use of the compositions, and kits and methods of using thereof are described herein. In a preferred aspect, the compositions are suitable for use in a method for forming a fibrin matrix or foam that can be applied or injected at the site of need. In another preferred aspect, the compositions are also suitable for use in methods for forming enhanced controlled delivery fibrin matrices that can be administered as gels or foams.Type: ApplicationFiled: December 23, 2008Publication date: July 2, 2009Inventors: Gaelle Charier, Manuela Muller-Maissen, Anna Jen
-
Publication number: 20070264227Abstract: Biomaterials containing a three-dimensional polymeric network formed from the reaction of a composition containing at least a first synthetic precursor molecule having n nucleophilic groups and a second precursor molecule having m electrophilic groups wherein the sum of n+m is at least five and wherein the sum of the weights of the first and second precursor molecules is in a range from about 8 to about 16% b weight of the composition, preferably from about 10 to about 15%, more preferably from about 12 to about 14.5% by weight of the composition. In one embodiment, the first and second precursor molecules are polyethylene glycols functionalized with nucleophilic and electrophilic groups, respectively. In a preferred embodiment, the nucleophilic groups are amino and/or thiol groups and the electrophilic groups are conjugated, unsaturated groups.Type: ApplicationFiled: April 13, 2007Publication date: November 15, 2007Inventors: Matthias Lutolf, Jason Schense, Anna Jen, Marina Capone, Jeffrey Hubbell
-
Publication number: 20070179093Abstract: Proteins are incorporated into protein or polysaccharide matrices for use in tissue repair, regeneration and/or remodeling and/or drug delivery. The proteins can be incorporated so that they are released by degradation of the matrix, by enzymatic action and/or diffusion. As demonstrated by the examples, one method is to bind heparin to the matrix by either covalent or non-covalent methods, to form a heparin-matrix. The heparin then non-covalently binds heparin-binding growth factors to the protein matrix. Alternatively, a fusion protein can be constructed which contains a crosslinking region such as a factor XIIIa substrate and the native protein sequence. Incorporation of degradable linkages between the matrix and the bioactive factors can be particularly useful when long-term drug delivery is desired, for example in the case of nerve regeneration, where it is desirable to vary the rate of drug release spatially as a function of regeneration, e.g.Type: ApplicationFiled: February 27, 2007Publication date: August 2, 2007Inventors: Matthias Lutolf, Jason Schense, Jeffrey Hubbell, Anna Jen
-
Patent number: 7247609Abstract: Proteins are incorporated into protein or polysaccharide matrices for use in tissue repair, regeneration and/or remodeling and/or drug delivery. The proteins can be incorporated so that they are released by degradation of the matrix, by enzymatic action and/or diffusion. As demonstrated by the examples, one method is to bind heparin to the matrix by either covalent or non-covalent methods, to form a heparin-matrix. The heparin then non-covalently binds heparin-binding growth factors to the protein matrix. Alternatively, a fusion protein can be constructed which contains a crosslinking region such as a factor XIIIa substrate and the native protein sequence. Incorporation of degradable linkages between the matrix and the bioactive factors can be particularly useful when long-term drug delivery is desired, for example in the case of nerve regeneration, where it is desirable to vary the rate of drug release spatially as a function of regeneration, e.g.Type: GrantFiled: December 18, 2002Date of Patent: July 24, 2007Assignees: Universitat Zurich, Eidgenossische Technische Hochschule ZurichInventors: Matthias Lütolf, Jason Schense, Jeffrey A. Hubbell, Anna Jen
-
Publication number: 20050065281Abstract: Biomaterial comprises a three dimensional polymeric network obtainable from the reaction of at least a first and second precursor molecule. The first precursor molecule is at least a trifunctional, branched component comprising at least three arms substantially similar in molecular weight and the second precursor molecule is at least a bifunctional component The ratio of equivalent weight or the functional groups of the first and second precursor molecule is in a range of between 0.9 and 1.1. The molecular weight of the arms of the first precursor molecule. the molecular weight of the second precursor molecule and the functionality of the branching points are selected so that the water content of the polymeric networks is between the equilibrium weight % and 92 weitht of the total weight of the polymeric network after completion of water uptake. The present invention teaches a way to improve characteristics of synthetic matrices which are useful for wound healing applications.Type: ApplicationFiled: November 7, 2002Publication date: March 24, 2005Inventors: Mathias Lutolf, Jason Schense, Anna Jen, Jeffrey Hubbell
-
Publication number: 20030187232Abstract: Proteins are incorporated into protein or polysaccharide matrices for use in tissue repair, regeneration and/or remodeling and/or drug delivery. The proteins can be incorporated so that they are released by degradation of the matrix, by enzymatic action and/or diffusion. As demonstrated by the examples, one method is to bind heparin to the matrix by either covalent or non-covalent methods, to form a heparin-matrix. The heparin then non-covalently binds heparin-binding growth factors to the protein matrix. Alternatively, a fusion protein can be constructed which contains a crosslinking region such as a factor XIIIa substrate and the native protein sequence. Incorporation of degradable linkages between the matrix and the bioactive factors can be particularly useful when long-term drug delivery is desired, for example in the case of nerve regeneration, where it is desirable to vary the rate of drug release spatially as a function of regeneration, e.g.Type: ApplicationFiled: December 17, 2002Publication date: October 2, 2003Applicant: Eidgenossische Technische Hochschule Zurich Universitat ZurichInventors: Jeffrey A. Hubbell, Jason C. Schense, Shelly E. Sakiyama-Elbert, Anna Jen
-
Publication number: 20030166833Abstract: Proteins are incorporated into protein or polysaccharide matrices for use in tissue repair, regeneration and/or remodeling and/or drug delivery. The proteins can be incorporated so that they are released by degradation of the matrix, by enzymatic action and/or diffusion. As demonstrated by the examples, one method is to bind heparin to the matrix by either covalent or non-covalent methods, to form a heparin-matrix. The heparin then non-covalently binds heparin-binding growth factors to the protein matrix. Alternatively, a fusion protein can be constructed which contains a crosslinking region such as a factor XIIIa substrate and the native protein sequence. Incorporation of degradable linkages between the matrix and the bioactive factors can be particularly useful when long-term drug delivery is desired, for example in the case of nerve regeneration, where it is desirable to vary the rate of drug release spatially as a function of regeneration, e.g.Type: ApplicationFiled: December 18, 2002Publication date: September 4, 2003Applicant: Eidgenossische Technische Hochschule ZurichInventors: Matthias Lutolf, Jason C. Schense, Jeffrey A. Hubbell, Anna Jen